InvestorsHub Logo
Followers 10
Posts 1085
Boards Moderated 0
Alias Born 12/31/2009

Re: Leonard1221 post# 1762

Friday, 04/05/2013 6:23:40 PM

Friday, April 05, 2013 6:23:40 PM

Post# of 7118
BAD NEWS for BISU. They took way too long and may be too late to make much out of Type2 Defense.

Johnson & Johnson First to Market with New Class of Type 2 Diabetes Drug

Johnson & Johnson received approval from the U.S. FDA on Friday for Invokana, a medication for the treatment of type 2 diabetes in a new class of drugs, sodium-glucose co-transporter 2 inhibitors, or SGLT2 inhibitors, reported USNews.com .

"Good things come to those who wait, not to those who hesitate."